Cargando…

Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study

BACKGROUND: Octreotide long-acting release (LAR) is a common drug used for acromegaly that aims to normalize serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1). However, only a few studies have evaluated its efficacy and safety in Chinese patients. This retrospective study aimed to a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Zhe, Duan, Lian, Gao, Daihui, Yao, Yong, Deng, Kan, Xing, Bing, Wang, Xinfeng, Tang, Yan, Zhu, Huijuan, Chen, Xiaoguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358514/ https://www.ncbi.nlm.nih.gov/pubmed/35957714 http://dx.doi.org/10.21037/atm-22-414

Ejemplares similares

Octreotide-Resistant Acromegaly: Challenges and Solutions
por: Corica, Giuliana, et al.
Publicado: (2020)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

Effect of octreotide on endometriosis in acromegaly: Case report with review of literature
por: Singh, Seerat, et al.
Publicado: (2014)

Octreotide use for rescue of vision in a pregnant patient with acromegaly
por: Hannon, Anne Marie, et al.
Publicado: (2019)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Oxalate nephropathy induced by octreotide treatment for acromegaly: a case report
por: Gariani, Karim, et al.
Publicado: (2012)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine
por: Zhao, Jie, et al.
Publicado: (2023)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment
por: Nomoto, Hiroshi, et al.
Publicado: (2019)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
por: Marques-Pamies, Montserrat, et al.
Publicado: (2023)

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Advanced acromegaly: successful disease control for more than 16 years using octreotide LA
por: Elshafie, Omayma, et al.
Publicado: (2020)

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2021)

Pituitary apoplexy causing spontaneous remission of acromegaly following long-acting octreotide therapy: a rare drug side effect or just a coincidence
por: Kumar, Sunil, et al.
Publicado: (2016)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide
por: Luty, Jacob, et al.
Publicado: (2021)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

Serum Levels of Asprosin, a Novel Adipokine, Are Significantly Lowered in Patients with Acromegaly
por: Ke, Xiaoan, et al.
Publicado: (2020)

Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review
por: Deng, Chao, et al.
Publicado: (2017)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive
por: Han, Bing, et al.
Publicado: (2021)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2023)

Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
por: Chin, Sang Ouk, et al.
Publicado: (2015)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR
por: Porto, Lara Benigno, et al.
Publicado: (2018)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
por: von Arx, Claudia, et al.
Publicado: (2020)

Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry
por: Long Bidin, Mohamed Badrulnizam, et al.
Publicado: (2023)

Safety of pregnancy in acromegaly patients and maternal and infant outcomes after pregnancy: single-center experience from China and review of the literature
por: Jiao, Rui, et al.
Publicado: (2023)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fgdgvt3kp5m91locduju8rd4ib